Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                CFSAN Constituent Updates

CFSAN Constituent Updates Home
          Food
          News & Events from CFSAN
          CFSAN Constituent Updates
          FDA Issues Response to Two Citizen Petitions on NAC in Dietary SupplementsCFSAN Constituent Updates FDA Issues Response to Two Citizen Petitions on NAC in Dietary Supplements
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintWhat's New

**Final Guidance Released**

The FDA is announcing the availability of a final guidance on FDA’s policy regarding products labeled as dietary supplements that contain N-acetyl-L-cysteine (NAC). This guidance explains our intent to exercise enforcement discretion with respect to the sale and distribution of certain NAC-containing products that are labeled as dietary supplements. This enforcement discretion policy applies to products that would be lawfully marketed dietary supplements if NAC were not excluded from the definition of “dietary supplement” and are not otherwise in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). This finalizes the draft guidance on this policy from April 2022. Please see the Federal Register Notice for additional information. Learn more at FDA Releases Final Guidance on Enforcement Discretion for Certain NAC Products.


Original Constituent Update

March 31, 2022

Today, the U.S. Food and Drug Administration (FDA) denied the request in two citizen petitions, from the Council for Responsible Nutrition (CRN) and the Natural Products Association (NPA), asking the agency to determine that products containing N-acetyl-L-cysteine (NAC) are not excluded from the definition of a dietary supplement under section 201(ff)(3)(B)(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

While the FDA’s response to the citizen petitions confirmed NAC is excluded from the definition of a dietary supplement, the agency has not yet reached a decision on the NPA citizen petition’s alternative request that the agency undertake rulemaking to allow the use of NAC in dietary supplements. The FDA continues to review this request. The agency’s November 24, 2021 tentative response to the petitions requested data, research results, and other information related to the safe use of NAC in products marketed as dietary supplements, and any safety concerns, to help us evaluate NPA’s rulemaking request. Once the FDA has completed its review of NPA’s alternative request, including review of additional information submitted to the docket in response to the request for information, the agency will respond to the remaining request in the NPA Petition.

In the interim, in light of the absence of safety concerns based on our review to date, among other factors, the FDA is considering exercising enforcement discretion for NAC-containing products labeled as dietary supplements that would be lawfully marketed dietary supplements if NAC were not excluded from the definition of dietary supplement and are not otherwise violative of the FD&C Act. The FDA intends to issue guidance about its policy on NAC-containing products labeled as dietary supplements in the near future.

**For Additional Information:**

Response to Council for Responsible Nutrition (CRN)
	Response to Natural Products Association (NPA)
	Council for Responsible Nutrition (CRN) Incoming Petition
	Natural Products Association (NPA) Incoming Petition
	Council for Responsible Nutrition (CRN) Tentative Response
	Natural Products Association (NPA) Tentative Response
	Dietary Supplements

                                                                                  Content current as of:
      04/21/2022
              
              
Regulated Product(s)
		 Dietary SupplementsCFSAN Constituent Updates
 Subscribe to CFSAN Constituent Updates
                        Get email updates delivered to your inbox.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop